Gregorio Moro

Time to Progression in Metastatic Breast Cancer Patients Treated With Epirubicin Is Not Improved by the Addition of Either Cisplatin or Lonidamine: Final Results of a Phase III Study With a Factorial Design

Alfredo Berruti, Raffaella Bitossi, G. Gorzegno et al. · Journal of Clinical Oncology · 2002 · 83 citations

Medicine, Oncology, Pharmacology +16

Beyond D’Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier

Domenico Gabriele, Barbara Alicja Jereczek‐Fossa, Marco Krengli et al. · Radiation Oncology · 2016 · 23 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Radiotherapy Alone or with Concomitant Daily Low-Dose Carboplatin in Locally Advanced, Unresectable Head and Neck Cancer: Definitive Results of a Phase III Study with a Follow-Up Period of up to Ten Years

Maria Grazia Ruo Redda, Riccardo Ragona, Umberto Ricardi et al. · Tumori Journal · 2010 · 22 citations

Medicine, Oncology, Radiation Oncology +13

Patient and Context Factors in the Adoption of Active Surveillance for Low-Risk Prostate Cancer

Giovannino Ciccone, Stefano De Luca, Marco Oderda et al. · JAMA Network Open · 2023 · 16 citations · Full text

Medicine, Radiation Oncology, Urology +16

Does Concomitant Chemoradiotherapy Influence Cosmetic Outcome in Conservative Treatment of Breast Cancer?

Gregorio Moro, M. Stasi, Valeria Casanova Borca · Tumori Journal · 1997 · 14 citations

Medicine, Oncology, Surgery +17